Broken String Biosciences Closes $15M Series A Funding Round · Broken String Biosciences, a UK-based genomics company building a technology platform to drive the development of cell and gene therapies that are safer by design, has closed a $15 million Series A investment round, co-led by Illumina Ventures and Mérieux…..
AlveoGene to develop inhaled gene therapies for rare respiratory diseases AlveoGene is a new gene therapy company created and funded by Oxford Science Enterprises, Harrington Discovery Institute and Old College Capital in partnership with six leading scientists from the UK Respiratory Gene Therapy Consortium (GTC). The Oxford-based company will use…..
MaaT Pharma and Skyepharma Complete Construction of Europe’s Largest Manufacturing Facility for Microbiome Ecosystem Therapies
MaaT Pharma and Skyepharma Complete Construction of Europe’s Largest Manufacturing Facility for Microbiome Ecosystem Therapies • Major milestone achieved with new state-of-the-art microbiome facility spanning over 1600 m², completed within the 12-month timeframe, further enhancing bioproduction capabilities and contributing to the ecosystem in France and Europe. • MaaT Pharma is…..
Advanced treatment for rare neurological “RASopathies” Parents’ initiative for affected children leads to a new EU research project RASopathies are a group of genetic diseases triggered by increased activation of the cellular RAS-MAPK signal pathway. This signal pathway has a decisive influence on growth and the differentiation of our cells.…..
Efficacy of gene therapy demonstrated in patients suffering from Crigler-Najjar Syndrome Crigler-Najjar syndrome is characterized by hyperbilirubinemia. If it is not treated quickly, the build-up of bilirubin, due to a deficiency in the liver enzyme UGT1A1, can cause significant neurological damage and become fatal. At the current time, the only…..
Quantoom Biosciences is growing in Evry Quantoom Biosciences, a Belgian biotech dedicated to mRNA production and part of the global life science group Univercells, is opening a brand-new facility in Évry-Courcouronnes (France). Following the SynHelix acquisition in 2021, Quantoom already had infrastructures in France, part of the Genopole campus, but…..
Pierre Fabre to commercialize and distribute the first approved allogeneic T-cell immunotherapy in Europe
Pierre Fabre to commercialize and distribute the first approved allogeneic T-cell immunotherapy in Europe Following transfer of the European Commission marketing authorization from Atara Biotherapeutics, Pierre Fabre is to lead launch and commercialization activities for Ebvallo® (tabelecleucel) in Europe The french group Pierre Fabre and Atara Biotherapeutics, a californian biotech…..
Creation of the Institut Pasteur-UCSF QBI Center of Excellence in Emerging Infectious Diseases Two academic and scientific heavyweights, the Institut Pasteur and UC San Francisco Quantitative Biosciences Institute (UCSF QBI), agree to implement joint actions towards the creation of a center of excellence in emerging infectious diseases with planned operations/locations…..
Longer life due to faulty RNA processing [caption id="" align="aligncenter" width="700"] The roundworm Caenorhabditis elegans is an important model organism in ageing research. The worm in the image is labelled with GFP::RNP-6. Credit: Max Planck Institute for Biology of Ageing[/caption] RNA is an important transmitter of information in our cells…..
Pegcetacoplan treatment shows increased effects over time in geographic atrophy Pegcetacoplan, a targeted C3 therapy designed to regulate excessive activation os the complement cascade, is on track to become the first treatment for geographic atrophy (GA) with a PDFU date of Nov. 26 and EU MAA submission on track by…..